Form 4: Sutro Biopharma Executive Linda Fitzpatrick Reports Stock Transactions

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Summary

• On March 4, 2024, Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• 9,125 shares were acquired through the vesting of RSUs.
• 3,739 shares were withheld by Sutro Biopharma to satisfy income tax obligations related to the RSU settlement; this was not a sale by Fitzpatrick.
• Following these transactions, Fitzpatrick directly owns 67,310 shares of Sutro Biopharma common stock.
• Additionally, 10,383 shares are held indirectly through the Michael A. & Linda A. Fitzpatrick Family Trust dated October 13, 1997.
• Fitzpatrick also holds 18,250 RSUs, each representing a contingent right to receive one share of Sutro Biopharma common stock upon settlement.

Sentiment

Score: 5

Explanation: This is a neutral reporting of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives and their potential alignment with shareholder interests.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by executives at comparable biotech companies like Amgen, Gilead Sciences, and Biogen, whenever they engage in stock transactions.
• The reporting requirements are governed by Section 16(a) of the Securities Exchange Act of 1934, ensuring a level playing field across the industry.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates